|
|
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
Philippe Moreau
,
Cyrille Hulin
,
Aurore Perrot
,
Bertrand Arnulf
,
Karim Belhadj
,
et al.
Article dans une revue
hal-03604926v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma
Anais Schavgoulidze
,
Valérie Lauwers-Cances
,
Aurore Perrot
,
Titouan Cazaubiel
,
Marie-Lorraine Chretien
,
et al.
Article dans une revue
hal-03801805v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau
,
Michel Attal
,
Cyrille Hulin
,
Bertrand Arnulf
,
Karim Belhadj
,
et al.
Article dans une revue
hal-03605015v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Long Term Follow-up of Hematopoietic Stem Cell Transplantation (HSCT) for Primary Plasma Cell Leukemia (pPCL): Final Results of a Prospective Study of IFM Group
Bruno Royer
,
Momar Diouf
,
Murielle Roussel
,
Lionel Karlin
,
Cyrille Hulin
,
et al.
Article dans une revue
hal-03605055v1
|
Partager
Gmail
Facebook
Twitter
LinkedIn
More
|